Veracyte (VCYT) Misses Q3 EPS by 26c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures take lead after Nvidia forecast refuels AI trade
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of Hormuz reopening
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Veracyte Announces Third Quarter 2023 Financial Results
November 7, 2023 4:05 PM EST
Grew Total Revenue to $90.1 million, an Increase of 19%
Grew Testing Revenue by 27%
Conference Call and Webcast Today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30,... More
